Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Seniors - 65 +
  • Georgia
  • Sandy Springs


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
    NCT04102007
    Condition:   Plaque Psoriasis
    Intervention:   Drug: Risankizumab
    Sponsor:   AbbVie
    Recruiting
  • Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
    NCT03827798
    Condition:   Hidradenitis Suppurativa
    Interventions:   Drug: CFZ533;   Drug: Placebo to CFZ533;   Drug: LYS006;   Drug: Placebo to LYS006
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A Study of LY3471851 in Participants With Psoriasis
    NCT04119557
    Condition:   Psoriasis
    Interventions:   Drug: LY3471851;   Drug: Placebo
    Sponsors:   Eli Lilly and Company;   Nektar Therapeutics
    Recruiting
  • A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
    NCT04015518
    Condition:   Palmoplantar Pustulosis (PPP)
    Interventions:   Drug: Spesolimab;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
    NCT04003389
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
    NCT04003142
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
    NCT03931785
    Condition:   Irritable Bowel Syndrome With Diarrhea (IBS-D)
    Interventions:   Drug: MD-7246;   Drug: Placebo
    Sponsors:   Ironwood Pharmaceuticals, Inc.;   Allergan Sales, LLC
    Recruiting
  • A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
    NCT03926169
    Condition:   Hidradenitis Suppurativa
    Interventions:   Drug: Risankizumab;   Drug: Placebo for risankizumab
    Sponsor:   AbbVie
    Recruiting
  • A Study to Assess the Efficacy, Safety and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
    NCT03858634
    Conditions:   Pruritus;   Chronic Idiopathic Urticaria;   Chronic Idiopathic Pruritus;   Lichen Planus;   Lichen Simplex Chronicus;   Plaque Psoriasis
    Interventions:   Drug: KPL-716;   Drug: Placebo
    Sponsor:   Kiniksa Pharmaceuticals, Ltd.
    Recruiting
  • Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa
    NCT03852472
    Conditions:   Hidradenitis Suppurativa;   Acne Inversa
    Interventions:   Drug: Avacopan;   Other: Placebo
    Sponsor:   ChemoCentryx
    Recruiting
  • Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-angle Glaucoma or Ocular Hypertension
    NCT03850782
    Conditions:   Glaucoma, Open-Angle;   Ocular Hypertension
    Intervention:   Drug: Bimatoprost (SR)
    Sponsor:   Allergan
    Recruiting
  • A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis
    NCT03816891
    Conditions:   Prurigo Nodularis;   Pruritis
    Interventions:   Drug: KPL-716;   Drug: Placebo
    Sponsor:   Kiniksa Pharmaceuticals, Ltd.
    Recruiting
  • Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
    NCT03736967
    Condition:   Atopic Dermatitis
    Interventions:   Drug: REGN3500;   Drug: Dupilumab;   Drug: REGN3500 + Dupilumab Combo;   Drug: Placebo
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • Effects of Pneumatic Vitreolysis on Macular Hole
    NCT03677869
    Conditions:   Vitreomacular Traction (VMT);   and Full-thickness Macular Holes (MH)
    Intervention:   Device: Intraocular gas (C3F8)
    Sponsors:   Jaeb Center for Health Research;   National Institutes of Health (NIH);   National Eye Institute (NEI)
    Recruiting
  • A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
    NCT03673501
    Condition:   Gastrointestinal Stromal Tumors
    Interventions:   Drug: ripretinib;   Drug: Sunitinib
    Sponsor:   Deciphera Pharmaceuticals LLC
    Recruiting
  • Effects of Pneumatic Vitreolysis on Vitreomacular Traction
    NCT03647267
    Condition:   Vitreomacular Traction
    Interventions:   Device: Pneumatic Vitreolysis (C3F8 injection);   Other: Observation
    Sponsors:   Jaeb Center for Health Research;   National Institutes of Health (NIH);   National Eye Institute (NEI)
    Recruiting
  • A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
    NCT01716806
    Conditions:   Hodgkin Disease;   Peripheral T Cell Lymphoma
    Interventions:   Drug: brentuximab vedotin;   Drug: bendamustine;   Drug: dacarbazine;   Drug: nivolumab
    Sponsors:   Seattle Genetics, Inc.;   Bristol-Myers Squibb
    Recruiting
  • A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
    NCT03835481
    Condition:   Psoriasis
    Interventions:   Drug: BI 730357;   Drug: Placebo to match BI 730357
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis
    NCT04178967
    Condition:   Atopic Dermatitis
    Interventions:   Biological: Lebrikizumab;   Other: Placebo
    Sponsor:   Dermira, Inc.
    Recruiting
  • Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
    NCT03987620
    Condition:   Candida Vulvovaginitis
    Interventions:   Drug: Ibrexafungerp;   Drug: Placebo
    Sponsors:   Scynexis, Inc.;   PPD
    Recruiting
  • Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
    NCT03903822
    Condition:   Atopic Dermatitis
    Interventions:   Drug: PF-06700841;   Drug: Vehicle (Placebo)
    Sponsor:   Pfizer
    Recruiting
  • Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
    NCT03428646
    Condition:   Dermatitis, Atopic
    Intervention:   Drug: Dupilumab
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
    NCT03422822
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC